Abstract
Clinical trials have demonstrated the superior clinical efficacy of dual antiplatelet therapy with a thienopyricline (a P2Y12 receptor blocker) and aspirin (COX-1 inhibitor) in patients undergoing stenting as well as patients with acute coronary syndromes. However, clopidogrel treatment is associated with a wide response variability and non-responsiveness in selected patients. The latter phenomenon is linked to the occurrence of recurrent ischaemic events including stent thrombosis in the recent studies. Prasugrel is a new thienopyricline derivative that produces more potent platelet inhibition and a rapid onset of action that is associated with irreversible P2Y12 receptor blockade. The latter properties of prasugrel may provide a superior alternative to clopidogrel, with less response variability and a decreased prevalence of non-responsiveness.
Original language | English (US) |
---|---|
Pages (from-to) | 1627-1633 |
Number of pages | 7 |
Journal | Expert Opinion on Investigational Drugs |
Volume | 15 |
Issue number | 12 |
DOIs | |
State | Published - Dec 1 2006 |
Keywords
- Non-responsiveness
- Platelet inhibition
- Prasugrel
- Thienopyridine
ASJC Scopus subject areas
- Pharmacology
- Pharmacology (medical)